Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Osteochondroma 1Non-alcoholic Fatty Liver Disease 1Nevus, Epithelioid and Spindle Cell 1Lung Neoplasms 1Hematologic Neoplasms 1Giant Cell Tumors 1Fibrosis 1Endometrial Hyperplasia 1Carcinoma, Lobular 1Carcinoma in Situ 1Barrett Esophagus 1

Interventions

Cyclophosphamide 22fludarabine 20venetoclax 8Whole-Body Irradiation 8Mycophenolic Acid 8Standard of Care 6Mesna 6Melphalan 6Azacitidine 6fludarabine phosphate 5Sirolimus 5thymoglobulin 4Thiotepa 4Tacrolimus 4Surveys and Questionnaires 4Specimen Handling 4Filgrastim 4Cytarabine 4entrectinib 3daratumumab 3cobimetinib 3alectinib 3Vemurafenib 3Rituximab 3Practice Guidelines as Topic 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Bortezomib 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hematologic Neoplasms × Sampling Studies × Clear all
NCT05463796 2025-08-07

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Dana-Farber Cancer Institute

Recruiting
5,000 enrolled
GastrointestinalGynecologicOther hematologic neoplasmThoracic

Barrett Esophagus, Carcinoma in Situ, Endometrial Hyperplasia, Fibrosis, Giant Cell Tumors, Lung Neoplasms, Osteochondroma, Carcinoma, Lobular, Nevus, Epithelioid and Spindle Cell, Hematologic Neoplasms, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡